Evidence map›Paper›PMID 27645771›Full record

ArticleSmall GTPases2018

PAK1 regulates inhibitory synaptic function via a novel mechanism mediated by endocannabinoids.

Shuting Xia, Zikai Zhou, Zhengping Jia

Open access · bronzeAbstract read
In one paragraph

Article in Small GTPases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Group I PAKs in myelin formation and repair of the central nervous system: what, when, and how.Biological reviews of the Cambridge Philosophical Society · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Shuting Xiaa The Key Laboratory of Developmental Genes and Human Disease, Southeast University , Nanjing , China.
Zikai Zhoua The Key Laboratory of Developmental Genes and Human Disease, Southeast University , Nanjing , China.
Zhengping Jiab Neurosciences and Mental Health Program, the Hospital for Sick Children , Toronto , Canada.
Southeast University · CNHospital for Sick Children · CA

Funding

CIHR MOP119421
6 · The paper itself

Abstract

The Rho family small GTPases and their effectors, including PAKs, are extensively studied in the context of the actin cytoskeleton, excitatory synaptic function, spine morphology and memory formation. However, their roles in inhibitory synaptic function remain poorly understood. We have recently shown that PAK1 is a potent regulator of GABAergic synaptic transmission. Thus, disruption of PAK1 leads to significant impairments in inhibitory postsynaptic currents which are manifested as reduced GABA presynaptic releases. Interestingly, this effect of PAK1 is distinct from its previously known role in spines and excitatory synaptic transmission in that it is independent of postsynaptic actin, but requires retrograde messengers produced and released from the postsynaptic neurons to suppress presynaptic GABA releases. We have further identified eCBs as the retrograde messengers and shown that PAK1 regulates the eCB signaling via restricting the tissue level of AEA by promoting synaptic expression of COX-2, a key enzyme to oxidize AEA. These results have established a novel pathway whereby PAK1, and by extension Rho proteins, regulates cellular processes, synaptic function and behaviors and have important implications in understanding and treating various diseases linked to PAKs and Rho signaling.

Indexed as

Endocannabinoidsp21-Activated KinasesSynapsesEndocannabinoidsp21-Activated Kinases2-AGAEAbrain disordersCOX-2EndocannabinoidsGABAPAKsRho GTPases

Identifiers

PMID27645771
PMCPMC5997138
OpenAlexW2521119438

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.